REGENXBIO Inc. RGNX

Company Overview

REGENXBIO Inc. is a U.S.-based biotechnology company focused on the development and commercialization of gene therapies. The company operates within the biotechnology and genetic medicines industries and is best known for its proprietary adeno-associated virus (AAV) gene delivery platform, known as NAV Technology Platform. REGENXBIO develops therapies for retinal diseases, neurodegenerative disorders, and other severe genetic conditions, while also generating revenue through licensing arrangements tied to its AAV intellectual property portfolio. The company’s business model combines internal therapeutic development with external partnerships and royalty-generating collaborations.

The company was founded in 2009 as a spinout from research conducted at the University of Pennsylvania related to AAV vectors and gene therapy innovation. Since its inception, REGENXBIO has expanded from a platform licensing business into a clinical-stage biotechnology company with proprietary therapeutic candidates. Its strategic positioning is supported by a broad patent estate covering AAV vectors and by partnerships with multiple biotechnology and pharmaceutical companies utilizing its vector technologies in clinical and commercial programs.